Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

Clinical and Translational Allergy20166:29 DOI: 10.1186/s13601-016-0116-9

REVIEW 

OPEN ACCESS

J Bousquet, J Farrell, G Crooks et al.

Email author

Abstract

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network.

It is deployed in collaboration with the World Health Organization Global Alliance against Chronic Respiratory Diseases (GARD). The European Innovation Partnership on Active and Healthy Ageing has proposed a 5-step framework for developing an individual scaling up strategy: (1) what to scale up: (1-a) databases of good practices, (1-b) assessment of viability of the scaling up of good practices, (1-c) classification of good practices for local replication and (2) how to scale up: (2-a) facilitating partnerships for scaling up, (2-b) implementation of key success factors and lessons learnt, including emerging technologies for individualised and predictive medicine. This strategy has already been applied to the chronic respiratory disease action plan of the European Innovation Partnership on Active and Healthy Ageing.

Download PDF

Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine

Allergology International
Vol. 65 (2016) No. 3 p. 243-252

Language:      English     Japanese   

http://doi.org/10.1016/j.alit.2016.04.011

INVITED REVIEW ARTICLE

Ioana Agache¹⁾, Cezmi A. Akdis^{2) 3)}

1) Faculty of Medicine, Transylvania University 2) Swiss Institute for Allergy and Asthma Research (SIAF), University of Zurich 3) Christine Kühne-Center for Allergy Research and Education (CK-CARE)

Released on J-STAGE 20160725  

Keywords: Allergic diseases; Asthma; Biomarkers; Endotypes; Precision medicine

•  Full Text PDF [1350K]

• Abstracts
• References(121)

Discoveries from basic science research in the last decade have brought significant progress in knowledge of pathophysiologic processes of allergic diseases, with a compelling impact on understanding of the natural history, risk prediction, treatment selection or mechanism-specific prevention strategies.

Allergy Blog Award UK 2017

Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence

REVIEW

 

OPEN ACCESS

• Pascal DemolyEmail author,
• Giovanni Passalacqua,
• Oliver Pfaar,
• Joaquin Sastre and
• Ulrich Wahn

Allergy, Asthma & Clinical Immunology201612:34

DOI: 10.1186/s13223-016-0140-2

Abstract

Allergy immunotherapy (AIT) is acknowledged to produce beneficial mid- and long-term clinical and immunologic effects and increased quality of life in patients with allergic respiratory diseases (such as allergic rhinoconjunctivitis and allergic asthma). However, poor adherence to AIT (due to intentional and/or non-intentional factors) is still a barrier to achieving these benefits. There is an urgent need for patient support programs (PSPs) that encompass communication, educational and motivational components.

Burden of asthma with elevated blood eosinophil levels

RESEARCH ARTICLE

 

OPEN ACCESS

 

OPEN PEER REVIEW

• Julian CascianoEmail author,
• Jerry A. Krishnan,
• Mary Buatti Small,
• Philip O. Buck,
• Gokul Gopalan,
• Chenghui Li,
• Robert Kemp and
• Zenobia Dotiwala

BMC Pulmonary MedicineBMC series – open, inclusive and trusted201616:100

DOI: 10.1186/s12890-016-0263-8

Open Peer Review reports

Abstract

Background

Asthma is a common chronic condition with an economic burden of almost $56 billion annually in the US. Biologic markers like blood eosinophils, that help predict the risk of exacerbation could help guide more optimal treatment plans and reduce cost. The purpose of this study was to determine whether healthcare resource use and expenditures vary by eosinophil level among patients with asthma.

Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

RESEARCH ARTICLE

 

OPEN ACCESS

 

OPEN PEER REVIEW

• Jutta BeierEmail author,
• Helena Pujol,
• Beatriz Seoane,
• Eulalia Jimenez,
• Carol Astbury,
• Eric Massana,
• Sandrine Ruiz and
• Gonzalo de Miquel

BMC Pulmonary MedicineBMC series – open, inclusive and trusted201616:102

DOI: 10.1186/s12890-016-0266-5

Open Peer Review reports

Abstract

Background

Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent. This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of abediterol in patients with moderate to severe COPD.

Dr. Phil Lieberman discusses the diagnosis and management of anaphylaxis

ACAAICOLA

Dr. Gary Salzman discusses the uses of pulmonary function tests for diagnosing respiratory disorders

ACAAICOLA